Vor Biopharma Secures $55.6M for Cancer Therapy Trials

The latest announcement is out from Vor Biopharma ( (VOR) ).

Don't Miss Our Christmas Offers:

Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical development and extend cash runway through 2025. The transaction involves significant stakeholders, including Reid Hoffman and RA Capital Management, and is expected to bolster Vor Bio’s efforts in advancing its clinical trials for cancer therapies, with updated data announcements anticipated in 2025.

More about Vor Biopharma

Vor Bio is a clinical-stage cell and genome engineering company focused on transforming the treatment of blood cancers by engineering hematopoietic stem cells to enhance targeted therapies post-transplant.

YTD Price Performance: -62.76%

Average Trading Volume: 555,431

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $57.55M

Learn more about VOR stock on TipRanks’ Stock Analysis page.

Trending Articles

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.